#depressionresearch — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #depressionresearch, aggregated by home.social.
-
DATE: August 6, 2026 at 02:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: The link between vitamin intake and depression largely vanishes when factoring in lifestyle
Higher vitamin intake may appear to be associated with fewer depressive symptoms, but most of these relationships disappear once differences in people’s health, socioeconomic circumstances, and behavior are considered, according to a study published in the Journal of Affective Disorders.
Vitamins perform numerous functions that could plausibly affect mental health. Vitamins B6, B9, and B12 contribute to processes involved in producing or regulating chemical messengers in the brain. Vitamins C and E help protect cells from potentially damaging molecules, while vitamin D may influence brain signaling and immune activity.
Previous studies have linked low levels of certain vitamins with depression, raising the possibility that improving nutrition could help prevent or reduce symptoms. However, the evidence has been inconsistent. People with higher vitamin intake may also differ in income, education, physical health, smoking, and other characteristics that independently affect depression risk.
The researchers therefore investigated whether vitamins remained associated with depression after considering these broader differences.
Led by Neil Mistry at Georgia Southern University, the team analyzed data from 26,170 adults (13,294 women, with an average age of 47.6 years) who participated in the National Health and Nutrition Examination Survey between 2005 and 2014.
Participants completed the nine-item Patient Health Questionnaire, a widely used measure producing a depression-symptom score from zero to 27. Of the participants, 75.35% had scores below five. Mild symptoms were recorded in 15.54%, moderate symptoms in 5.60%, moderately severe symptoms in 2.48%, and severe symptoms in 1.02%.
Intake of vitamins A, C, D, and E was estimated by asking participants what they had consumed during the preceding 24 hours. Vitamins B6, B9—also known as folate—and B12 were assessed using blood samples. The researchers also constructed an exploratory score intended to represent overall nutrition.
Initial analyses suggested that higher levels of several vitamins were associated with lower odds of depressive symptoms. Vitamins C, D, and E, for example, were inversely associated with having a score of at least five before other factors were considered. However, these associations were no longer statistically significant after adjustment for age, sex, education, poverty, race, body mass index, health limitations, alcohol intake, and tobacco use.
A similar pattern emerged for more serious symptoms. Apparent relationships involving vitamins A and E weakened after adjustment. Vitamin B12 was not consistently associated with depression, and the overall nutritional score also showed no independent relationship.
Vitamin B6 provided an exception. Higher blood concentrations were associated with lower odds of scoring 15 or above, indicating at least moderately severe symptoms, after the researchers adjusted for other factors. The estimated change associated with each additional unit of B6 was small, however, and should not be interpreted as proof that B6 prevents or treats depression.
As the authors concluded, “These findings do not support strong independent associations between vitamin intake and depression presence or severity after accounting for confounding factors.”
The results instead suggest that some apparent vitamin–depression relationships may reflect wider patterns. Greater depression severity was also associated with lower income, lower educational attainment, poorer self-rated health, physical or sleep limitations, tobacco use, and being unmarried. These circumstances can influence both diet and mental health.
Some limitations are to be noted. For instance, the models did not account for antidepressants, other psychiatric medications, or supplements. Moreover, one day of recalled food intake may poorly represent a person’s normal diet.
The study, “Associations between vitamin intake and depression severity: A cross-sectional analysis of NHANES 2005–2014,” was authored by Neil Mistry, Logan T. Cowan, Hani M. Samawi, Amenah Qotineh, Ousainou Gomez, and Kelly L. Sullivan.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #VitaminIntake #DepressionResearch #NHANES #MentalHealthNutrition #VitaminsAndDepression #B6B9B12 #VitaminD #LifestyleFactors #SocioeconomicStatus #PublicHealthStudy
-
DATE: July 30, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Scientists are using biological markers to take the guesswork out of depression treatment
A recent study published in Nature Mental Health suggests that using biological and behavioral markers can help predict how well a person with depression will respond to common medications. By evaluating specific brain patterns and cognitive traits before treatment, scientists found evidence that certain patients are much more likely to experience symptom relief from antidepressants. These findings provide a foundation for developing personalized treatment plans that could reduce the time and guesswork typically involved in finding the right medication for depression.
Major depressive disorder affects millions of people, yet finding an effective treatment often relies on a trial and error process. A patient might take a medication for a month or more before knowing if it works, and a large portion of individuals do not experience adequate relief from the first drug they try.
“Treating depression still involves too much trial and error: only about 30-50% of patients respond to the first antidepressant they receive, and it can take several weeks to determine whether a medication is working,” said Diego A. Pizzagalli, founding director of UC Irvine’s Noel Drury, M.D. Institute for Translational Depression Discoveries and distinguished professor of psychiatry and human behavior, neurobiology and behavior, and biomedical engineering.
To reduce this waiting period and improve outcomes, scientists are searching for objective signs that might predict a person’s response to specific drugs before a prescription is written. These objective signs are known as biomarkers, which are measurable indicators of a biological state or condition. For depression, a biomarker might be a specific pattern of brain activity, a cognitive trait, or even a demographic factor like a person’s employment status. By identifying these markers, clinicians might eventually match patients with the exact medication most likely to help them.
In this context, the study aimed to predict responses to two widely prescribed antidepressants: sertraline and bupropion. Pizzagalli explained the reasoning behind looking at these specific options. “We wanted to test whether information collected before treatment, including brain connectivity, reward learning, cognitive performance, and clinical characteristics, could help identify who is most likely to benefit from two commonly prescribed antidepressants, sertraline and bupropion,” he said.
Sertraline belongs to a class of drugs that increases levels of the chemical serotonin in the brain to help regulate mood. Bupropion operates differently, targeting other brain chemicals called dopamine and norepinephrine, which are associated with motivation and reward processing. Because these drugs work through different chemical pathways, researchers suspected that distinct biological profiles might indicate which medication tends to be most effective for an individual patient.
The authors first developed a predictive tool using data from a previous large clinical trial known as the EMBARC study. “An important feature of this work is that we did not simply examine existing treatment data after the fact,” Pizzagalli said. “We first developed the prediction models in an earlier, independent study and then tested them prospectively in a double-blind clinical trial, making this an unusually rigorous early test of biomarker-guided antidepressant treatment.”
To build this predictive algorithm, the researchers examined various potential biomarkers, including demographic details like employment status and clinical factors such as depression severity and personality traits like neuroticism. They also included specific cognitive tests and brain imaging data to round out the predictive tool. By analyzing these past records, they built a mathematical model to identify the key traits of people who responded well to each medication.
One specific measure in this model involved functional magnetic resonance imaging, or fMRI. This technology measures brain activity by detecting changes in blood flow over time, allowing scientists to see how different regions communicate. The researchers looked at the resting connection between two brain areas involved in processing rewards and regulating emotions. These two regions are the nucleus accumbens, located deep within the brain, and the rostral anterior cingulate cortex, situated near the front of the brain.
Along with brain scans, the predictive tool incorporated specific behavioral tests to measure cognitive functions. Participants completed a computer-based assessment called the Probabilistic Reward Task to measure reward sensitivity, which evaluates how strongly a person responds to positive feedback. They also completed a cognitive control assessment known as the Flanker task, which measures a person’s ability to focus on specific targets while actively ignoring distracting information.
By combining these diverse data points, the algorithm assigned a positive or negative marker for both sertraline and bupropion. To test this algorithm in real time, the researchers enrolled a new group of 48 unmedicated adults experiencing major depression. Each participant underwent the baseline MRI scans, cognitive assessments, and clinical interviews. Researchers used standardized clinical questionnaires, such as the Montgomery-Åsberg Depression Rating Scale, to quantify the exact severity of each participant’s depressive symptoms before starting any treatment.
Within a few days of these initial tests, the algorithm analyzed the new participants’ data to determine their biological markers. Out of the original group, 47 participants completed at least one week of treatment and were included in the main analysis. Following their biomarker assessment, participants were randomly assigned to receive either sertraline or bupropion.
Half of the group received a medication that was consistent with their biological marker, meaning the algorithm predicted they would respond well to it based on their specific biology. The other half received a medication that was inconsistent with their marker profile. To prevent any bias, the trial was double-blind, meaning neither the patients nor the doctors evaluating them knew which specific medication had been prescribed or what the biomarker results were.
The researchers tracked the participants’ depression symptoms throughout an eight week period to see how they progressed. They anticipated that individuals matched with the correct drug would show a stronger improvement. “We expected people to do better when they received the specific medication indicated by their biomarker profile, but that was not what we found,” Pizzagalli told PsyPost.
“Instead, the markers appeared better at distinguishing people who were generally more likely, or less likely, to respond to either medication: the response rate was approximately 71% among participants with positive markers for both drugs, compared with about 43% among those with neither marker,” Pizzagalli said. The data showed that assigning a drug strictly based on an aligned marker did not produce a statistically significant difference in symptom relief compared to an unaligned assignment. The specific medication a participant received seemed to matter less than the overall presence of positive biomarkers.
Regardless of the drug assignment, participants who possessed positive markers for both drugs, or at least one of the drugs, experienced greater reductions in their depression symptoms than those who had two negative markers. Individuals with a marker for just one of the drugs had a response rate of 65.4 percent. The study defined a response as a 50 percent or greater reduction in clinical depression scores from the beginning to the end of the trial.
“Our results offer an encouraging but preliminary step toward making depression treatment more personalized,” Pizzagalli said. “Participants whose profiles included at least one positive treatment-response marker improved more than those whose profiles suggested that neither medication was likely to help; however, the markers did not reliably tell us whether sertraline or bupropion was the better choice for a particular individual.”
There are some potential misinterpretations that readers should avoid. “These findings do not mean that a brain scan or behavioral test can currently tell a patient which antidepressant to take,” Pizzagalli said. “This was a relatively small study, and our primary comparison, whether patients did better when matched to the medication indicated by their markers, was not statistically significant; the findings therefore need to be replicated in substantially larger and more diverse samples.”
The reliance on functional magnetic resonance imaging presents another practical barrier for widespread clinical application. Brain scans are expensive, time consuming, and require specialized equipment that is not easily accessible in everyday primary care settings. Additionally, variations in how different MRI machines process data can make it difficult to generalize the algorithm across different hospitals or research centers.
Addressing these logistical hurdles will require establishing standardized procedures across the medical field. “The next step is to test and refine these prediction models in larger, multisite clinical trials,” Pizzagalli said. “We also want to develop markers that are easier and less expensive to use in routine care, and to determine whether different profiles predict response not only to conventional antidepressants, but also to treatments such as brain stimulation, ketamine, and other rapid-acting therapies.”
The study, “A precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design,” was authored by Peter Zhukovsky, Manuel Kuhn, Lauren R. Borchers, Boyu Ren, Sarah E. Woronko, Mohan Li, Choi Sze Tracy Lam, Ethan M. Zhang, Kerry J. Ressler, Brian P. Brennan, Gordana Vitaliano, and Diego A. Pizzagalli.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #DepressionBiomarkers #PrecisionMentalHealth #BiomarkerGuidedTreatment #DepressionResearch #fmri #sertraline #bupropion #MentalHealthInnovation #PersonalizedMedicine #NatureMentalHealth
-
🧠 Could gut metabolites hold the key to enhancing antidepressant effects?
🔗 Does isovaleric acid play a key role in the interaction between probiotics and antidepressants? A secondary analysis of a randomized clinical trial. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.05.035
📚 CSBJ: https://www.csbj.org/
#GutBrainAxis #MentalHealth #Probiotics #DepressionResearch #Psychobiotics #Microbiome
-
New study finds a surprising connection between oral bacteria and depression—your mental health might start in your mouth. #MentalHealth #OralMicrobiome #DepressionResearch
https://geekoo.news/depression-may-start-with-the-bacteria-in-your-mouth/
-
Our study explores innovative strategies to prolong the antisuicidal effects of ketamine in individuals with treatment-resistant depression, a critical step toward improving outcomes for patients in crisis.
This recognition not only supports early-career researchers like myself, but also strengthens our collective mission to advance evidence-based care for depression and suicidality.
#ADAA2025 #SuicidePrevention #DepressionResearch #CareerDevelopment #ClinicalTrials #MentalHealthResearch
-
🧠 Breakthrough in depression research! 🔬 Stanford Medicine identifies 6 distinct depression "biotypes" using fMRI & machine learning. This could revolutionize treatment by predicting responses based on brain patterns. A step towards personalized mental health care! 🎯💊
#DepressionResearch #MentalHealth #PrecisionMedicine
https://med.stanford.edu/news/all-news/2024/06/depression-biotypes.html